Walgreens Boots Alliance Inc
WBA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$88.00 | Ftdg | Byhl |
Walgreens Provides Solid 2023 Outlook, Despite Headwinds Kicking In During Fourth Quarter
Although no-moat Walgreens Boots Alliance reported weak fiscal 2022 fourth-quarter results relative to last year, it delivered ahead of fiscal-year expectations. We plan to mildly adjust our long-term assumptions to better account for likely growth in the U.S. healthcare segment but expect to maintain our $48 fair value estimate at first glance. The shares appear significantly undervalued to us.